Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
نویسندگان
چکیده
L -DOPA is the criterion standard of treatment for Parkinson disease. Although it alleviates some Parkinsonian symptoms, long-term induces -DOPA–induced dyskinesia (LID). Several theoretical models including firing rate model, pattern and ensemble model are proposed to explain mechanisms LID. The “firing model” proposes that decreasing mean rates output nuclei basal ganglia (BG) globus pallidus internal segment substantia nigra reticulata, along BG pathways, dyskinesia. claimed abnormal a single unit activity local field potentials may disturb information processing in BG, resulting “ensemble described symptoms might represent distributed impairment involving many brain regions, but number activated neurons striatum correlated most strongly with severity. Extensive evidence circuit driving LID has also been presented. multisystem disease affects wide areas brain. Brain regions striatum, pallidal–subthalamic network, motor cortex, thalamus, cerebellum all involved pathophysiology In addition, although both amantadine deep stimulation help reduce LID, these approaches have complications limit their use, novel antidyskinetic drug needed; require us understand mechanism more deeply.
منابع مشابه
Levetiracetam in L-dopa-induced dyskinesia.
Dyskinesia To the Editor: Levetiracetam is a novel antiepi-leptic drug used in the treatment of the partial crisis as an add-on to other antiepileptic drugs. Although the underlying mechanism of action of levetirace-tam is unknown, the metabolism of GABA appears to be involved. In particular , it may counteract neuronal hyper-synchronization of the firing patterns of neurons in the substantia n...
متن کاملThe pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, long-term administration of L-DOPA is marred by the emergence of abnormal involuntary movements, i.e., L-DOPA-induced dyskinesia (LID). Years of intensive research have yielded significant progress in the quest to elucidate the mechanisms leading to the development and ex...
متن کاملDrug-induced dyskinesia--an electrophysiological analysis of dyskinesia induced by L-DOPA and anticholinergic drugs.
The application of L·DOPA (L-3, 4-dihydroxyphenylalanine) to the treatment of extrapyramidal disorders has been extremely beneficial for parkinsonism 1)-8). At the same time several side-effects have been recognized. Among them, the appearance of dyskinesia poses an important problem 8)-13l , but causative mechanisms of L·DOPA induced dyskinesia are not yet sufficiently elucidated. Such dyskine...
متن کاملNitric oxide, a new player in L-DOPA-induced dyskinesia?
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, the long-term use of L-DOPA causes, in combination with disease progression, the development of motor complications termed L-DOPA-induced dyskinesia (LID). LID is the result of profound modifications in the functional organization of the basal ganglia circuitry. There is ...
متن کاملPresynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's disease (PD) for over 40 years. However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy. There is wide consensus that these motor complications depend on both ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neuroscience
سال: 2021
ISSN: ['1662-453X', '1662-4548']
DOI: https://doi.org/10.3389/fnins.2021.614412